Author response: Preserving stroke care during the COVID-19 pandemic: Potential issues and solutions

  • Enrique Leira, MD, MS, University of Iowa
  • Andrew N. Russman, DO, Cleveland Clinic Foundation
  • Mitchell S.V. Elkind, MD, MS, MPhil, Columbia University
  • Bradford B. Worrall, MD, University of Virginia
Submitted May 19, 2020

We thank Dr. Machado for his thoughtful comment on our article.1 We agree that the observation of hemostatic and coagulopathic derangements in some COVID-19 patients and the observation of stroke and other vascular events warrants investigation—and, in particular randomized clinical trials—to test appropriate therapies. Fortunately several investigators are actively conducting randomized controlled trials of anticoagulation in COVID (+) hospitalized patients, including both multicenter2 and single center trials in heavily affected areas.3

Disclosure

The authors report no relevant disclosures. Contact journal@neurology.org for full disclosures.

References

  1. Leira EC, Russman AN, Biller J, et al. Preserving stroke care during the COVID-19 pandemic: Potential issues and solutions. Neurology 2020 Epub May 8.
  2. Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care. In: ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT04362085.
  3. Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 (IMPROVE). In: ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT04367831.

Navigate back to article